EUVIMEDScopri EUVIMED
Randomisierte kontrollierte StudieVergleichsstudie

Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease

Fatima Nari, Jooyeop Lee iD, Joohee Kim, Soo Lim iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71265 ↗

At a glance

Randomisierte kontrollierte Studie in Diabetes, Obesity and Metabolism, 2026. Written by Fatima Nari and 3 co-authors. Institution: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Major MEDLINE topics: Diabetes Mellitus, Type 2, Succinates, Aspirin, Blood Viscosity. 39 references. Funded by: Daewoong Pharmaceutical Company.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Whole blood viscosity (WBV) is associated with impaired microvascular circulation and cardiovascular risk in patients with Type 2 diabetes mellitus (T2DM) and peripheral artery disease (PAD). This study investigated the efficacy and safety of sarpogrelate compared with aspirin on WBV in patients with T2DM and PAD.

Methods

This randomised, open‐label clinical trial enrolled adults with T2DM and PAD. A total of 66 participants were randomised to aspirin ( n = 33) or sarpogrelate ( n = 33) for 24 weeks. The primary endpoint was change in diastolic WBV at a shear rate of 1 s −1 from baseline to week 24. Secondary endpoints included tissue oxygen delivery index, pain visual analogue scale (VAS) and cold sensation scores.

Results

After 24 weeks, diastolic WBV did not decrease significantly in both groups (sarpogrelate group: 31.91 ± 7.83 to 30.76 ± 7.08, mean change, −1.15 ± 9.25; p = 0.509; aspirin group: 33.32 ± 8.86 to 32.12 ± 9.60, mean change, −1.20 ± 8.36; p = 0.432). VAS scores improved significantly in both groups (mean change, −9.09 ± 18.09; p = 0.007 for sarpogrelate; −6.13 ± 16.47; p = 0.047 for aspirin), with no between‐group difference. Cold sensation scores improved only in the sarpogrelate group (mean change, −0.21 ± 0.55; p = 0.033 vs. −0.23 ± 0.85; p = 0.147 for aspirin group), with no between‐group difference.

Conclusion

In patients with T2DM and PAD, sarpogrelate did not significantly improve WBV compared with aspirin. VAS scores and cold sensation improved significantly within the sarpogrelate group with no between‐group difference.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2SuccinatesAspirinBlood ViscosityPeripheral Arterial DiseaseDiabetic AngiopathiesPlatelet Aggregation InhibitorsHumansFemaleMaleMiddle AgedAgedTreatment Outcome

Author keywords

5‐HT2A receptoraspirinperipheral artery diseasesarpogrelatetype 2 diabetes mellituswhole blood viscosity

Substances

sarpogrelateSuccinatesAspirinPlatelet Aggregation Inhibitors

Authors and institutions

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

ORCID profiles: Jooyeop Lee, Soo Lim

Funding

  • Daewoong Pharmaceutical Company

Cite

APA

Nari, F., Lee, J., Kim, J., & Lim, S. (2026). Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71265

Vancouver

Nari F, Lee J, Kim J, Lim S. Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71265

BibTeX
@article{Nari2026,
  author = {Nari, Fatima and Lee, Jooyeop and Kim, Joohee and Lim, Soo},
  title = {Effects of Sarpogrelate Versus Aspirin on Whole Blood Viscosity in Patients With Type 2 Diabetes and Peripheral Artery Disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71265}
}
Start for free →